

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Norry Elliot</u> (Last) (First) (Middle) <u>103 CHURCH STREET, APARTMENT 20</u> (Street) <u>PHILADELPHIA PA 10106</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/13/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>Adaptimmune Therapeutics PLC [ADAP]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Medical Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Ordinary Shares with a nominal value of GBP0.001 per share⁽¹⁾</u>	<u>2,679</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Option to purchase Ordinary Shares</u>	<u>(2)</u>	<u>01/08/2026</u>	<u>Ordinary Shares</u>	<u>200,000</u>	<u>1.28⁽³⁾</u>	<u>D</u>	
<u>Option to purchase Ordinary Shares</u>	<u>(4)</u>	<u>01/13/2027</u>	<u>Ordinary Shares</u>	<u>63,024</u>	<u>0.72⁽⁵⁾</u>	<u>D</u>	
<u>Option to purchase Ordinary Shares</u>	<u>(6)</u>	<u>07/07/2027</u>	<u>Ordinary Shares</u>	<u>300,000</u>	<u>0.81⁽⁷⁾</u>	<u>D</u>	
<u>Option to purchase Ordinary Shares</u>	<u>(8)</u>	<u>01/12/2028</u>	<u>Ordinary Shares</u>	<u>79,824</u>	<u>1.3⁽⁹⁾</u>	<u>D</u>	
<u>Option to purchase Ordinary Shares</u>	<u>(10)</u>	<u>(11)</u>	<u>Ordinary Shares</u>	<u>40,266</u>	<u>0.0014⁽¹²⁾</u>	<u>D</u>	
<u>Option to purchase Ordinary Shares</u>	<u>(13)</u>	<u>(14)</u>	<u>Ordinary Shares</u>	<u>40,266</u>	<u>0.0013⁽¹⁵⁾</u>	<u>D</u>	
<u>Option to purchase Ordinary Shares</u>	<u>(16)</u>	<u>01/04/2029</u>	<u>Ordinary Shares</u>	<u>79,824</u>	<u>0.89⁽¹⁷⁾</u>	<u>D</u>	

Explanation of Responses:

1. Represented by 2,679 American Depositary Shares ("ADS") held by Dr. Norry. Dr. Norry holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer.
2. 200,000 Ordinary Shares granted January 18, 2016, which are fully vested and exercisable (vesting start date is deemed to be July 1, 2015).
3. The exercise price was converted from GBP0.89 based on an exchange rate of U.S.\$1.4309 to GBP1.00. The actual exercise price will be the pounds sterling amount.
4. Exercisable as to 15,756 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 1,313 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021.
5. The exercise price was converted from GBP0.59 based on an exchange rate of U.S.\$1.2219 to GBP1.00. The actual exercise price will be the pounds sterling amount.
6. Exercisable as to 75,000 Ordinary Shares on July 7, 2018 and will be exercisable as to the remainder in monthly installments of 6,250 Ordinary Shares on the seventh of each month from August 7, 2018 through July 7, 2021.
7. The exercise price was converted from GBP0.62 based on an exchange rate of U.S.\$1.2949 to GBP1.00. The actual exercise price will be the pounds sterling amount.
8. Exercisable as to 19,956 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 1,663 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.
9. The exercise price was converted from GBP0.96 based on an exchange rate of U.S.\$1.3542 to GBP1.00. The actual exercise price will be the pounds sterling amount.
10. Exercisable as to 13,422 Ordinary Shares on January 12, 2020 and will be exercisable as to the remainder in annual installments of 13,422 Ordinary Shares on the twelfth of each January from January 12, 2021 through January 12, 2022.
11. The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
12. The exercise price was converted from GBP0.001 based on an exchange rate of U.S.\$1.3542 to GBP1.00. The actual exercise price will be the pounds sterling amount.
13. Exercisable as to 13,422 Ordinary Shares on January 4, 2021 and will be exercisable as to the remainder in annual installments of 13,422 Ordinary Shares on the fourth of each January from January 4, 2022 through January 4, 2023.
14. The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

15. The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.\$1.2633 to GBP1.00. The actual exercise price will be the pounds sterling amount.

16. Exercisable as to 19,956 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 1,663 Ordinary Shares on the fourth of each month from February 4, 2020 through January 4, 2023.

17. The exercise price was converted from GBP0.70, based on an exchange rate of U.S.\$1.2633 to GBP1.00. The actual exercise price will be the pounds sterling amount.

/s/ Elliot Norry

01/13/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.